Related Experiment Videos
Modeling the epidermal growth factor -- epidermal growth factor receptor l2 domain interaction: implications for the
Robert N Jorissen1, Herbert R Treutlein, V Chandana Epa
1The Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia. robert.jorissen@ludwig.edu.au
Journal of Biomolecular Structure & Dynamics
|May 25, 2002
Summary
Researchers modeled epidermal growth factor (EGF) binding to its receptor, revealing how EGF interacts with the receptor's L2 domain. This structural insight aids in designing new EGF receptor antagonists.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Signaling
Background:
- Epidermal Growth Factor (EGF) receptor signaling is crucial for cell growth and is initiated by ligand binding and receptor dimerization.
- Understanding the structural basis of ligand-bound EGF receptor complexes is essential but has been limited by a lack of structural data.
Purpose of the Study:
- To model the three-dimensional structure of the complex formed between EGF and the major ligand-binding domain of the EGF receptor.
- To provide structural insights into the interaction mechanism for the design of novel receptor antagonists.
Main Methods:
- Utilized an NMR-derived structure of EGF.
- Employed a homology model of the EGF receptor's major ligand-binding domain (L2 domain).
- Integrated experimental data to construct a low-resolution structural model of the EGF-EGF receptor complex.
Main Results:
- The model shows EGF binding across a specific face of the EGF receptor L2 domain.
- Identified specific EGF residues (10-16, 36-37, 40-47) involved in this interaction.
- The model supports a two-step ligand-binding process, consistent with existing TGF-alpha interaction data.
Conclusions:
- A structural model of EGF bound to the EGF receptor L2 domain has been generated.
- The findings suggest a multi-step binding mechanism for EGF receptor activation.
- This structural model can guide the development of targeted EGF receptor antagonists.